Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$66.30
-2.6%
$62.88
$52.50
$77.00
$1.47B0.57319,965 shs326,192 shs
Biohaven Ltd. stock logo
BHVN
Biohaven
$14.04
-7.1%
$15.31
$13.04
$55.70
$1.43B0.911.32 million shs1.88 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.19
-3.2%
$6.84
$4.58
$9.78
$372.52M1.89476,422 shs405,537 shs
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$26.40
-4.9%
$24.62
$22.48
$71.71
$1.64B2.86876,731 shs908,736 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-2.56%+2.06%+2.54%-4.20%+5.27%
Biohaven Ltd. stock logo
BHVN
Biohaven
-7.50%+1.08%-2.36%-31.20%-61.31%
CryoPort, Inc. stock logo
CYRX
CryoPort
-3.23%-4.77%+6.05%+29.55%-15.11%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-4.86%+4.97%+16.20%-11.08%-39.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.9502 of 5 stars
2.51.00.03.33.83.31.3
Biohaven Ltd. stock logo
BHVN
Biohaven
3.2271 of 5 stars
4.51.00.00.02.22.50.6
CryoPort, Inc. stock logo
CYRX
CryoPort
2.4538 of 5 stars
3.41.00.00.02.82.50.6
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
2.2322 of 5 stars
3.51.00.00.02.92.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.00
Buy$78.8818.97% Upside
Biohaven Ltd. stock logo
BHVN
Biohaven
3.07
Buy$58.46316.39% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.75
Moderate Buy$10.8851.25% Upside
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3.08
Buy$91.89248.06% Upside

Current Analyst Ratings Breakdown

Latest CYRX, JANX, BHVN, and ANIP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$65.00
7/10/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$84.00
7/7/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $10.00
6/18/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$68.00 ➝ $55.00
5/19/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.00
5/13/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/13/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.00
5/12/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$86.00 ➝ $86.00
5/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/28/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$60.00 ➝ $57.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$614.38M2.34$7.40 per share8.96$19.11 per share3.47
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/A$4.19 per shareN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.58N/AN/A$7.44 per share0.97
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$10.59M147.51N/AN/A$19.49 per share1.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-$18.52M-$1.27N/A15.75N/A-3.12%21.35%7.52%8/5/2025 (Estimated)
Biohaven Ltd. stock logo
BHVN
Biohaven
-$846.42M-$9.36N/AN/AN/AN/A-257.07%-164.01%8/5/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$68.99M-$1.36N/AN/AN/AN/A-9.29%-8.89%8/6/2025 (Estimated)

Latest CYRX, JANX, BHVN, and ANIP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q1 2025
Biohaven Ltd. stock logo
BHVN
Biohaven
-$1.94N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.50N/AN/AN/A$0.30 millionN/A
8/5/2025Q2 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.49N/AN/AN/A$187.18 millionN/A
8/5/2025Q2 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20N/AN/AN/A$41.74 millionN/A
5/12/2025Q1 2025
Biohaven Ltd. stock logo
BHVN
Biohaven
-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A
5/9/2025Q1 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.37$1.70+$0.33$0.69$179.75 million$197.12 million
5/8/2025Q1 2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
1.46
2.66
1.98
Biohaven Ltd. stock logo
BHVN
Biohaven
N/A
2.33
2.33
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/A
58.47
58.47

Institutional Ownership

CompanyInstitutional Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
Biohaven Ltd. stock logo
BHVN
Biohaven
88.78%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
75.39%

Insider Ownership

CompanyInsider Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
11.10%
Biohaven Ltd. stock logo
BHVN
Biohaven
16.00%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
8.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
60021.66 million19.26 millionOptionable
Biohaven Ltd. stock logo
BHVN
Biohaven
239102.11 million85.78 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.12 millionOptionable
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3059.17 million54.38 millionOptionable

Recent News About These Companies

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
Janux Therapeutics Becomes Oversold (JANX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANI Pharmaceuticals stock logo

ANI Pharmaceuticals NASDAQ:ANIP

$66.30 -1.74 (-2.56%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$66.36 +0.06 (+0.08%)
As of 07/18/2025 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Biohaven stock logo

Biohaven NYSE:BHVN

$14.04 -1.07 (-7.08%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$14.10 +0.06 (+0.43%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.19 -0.24 (-3.23%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$7.29 +0.10 (+1.39%)
As of 07/18/2025 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Janux Therapeutics stock logo

Janux Therapeutics NASDAQ:JANX

$26.40 -1.35 (-4.86%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$26.40 +0.01 (+0.02%)
As of 07/18/2025 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.